Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Statins are commonly prescribed to lower LDL cholesterol. Clinical guidelines recommend 30-50% reduction within 3 months, yet many patients do not achieve this. We investigated the impact of patient characteristics and genetics on LDL-c reduction, treatment adherence, and adverse clinical outcomes.
Methods
We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median=16 days prior, IQR=28) and within a year of starting treatment (median=89 days, IQR=125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within one year of statin initiation, genetic factors, post-treatment LDL reduction, and clinical adverse outcomes. For 13,000 patients with ≥3 LDL-c measures, we used inverse probability weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally.
Results
Predictors of LDL-c reduction following statin initiation included the time until the 1 st measurement, PDC, and the pharmacogenetic variant SLCO1B1 *5. LDL-c reduction was greater in those with high adherence versus lower adherence (38% reduction when PDC>95% [high] vs. 15% when PDC<50% [low]). Longitudinal causal modelling showed that the most recent PDC measure exerted the largest influence on overall LDL-c reduction, followed by the initial PDC.
Genetic predictors of reduced PDC included liability to schizophrenia (Coef top 20% -1.94, 95%CI -2.69 to -1.19), whilst genetic liability to cardiovascular diseases increased PDC (Coef top 20% 1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09-1.54) and cataract (HR 1.20, 95%CI 1.07-1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73-0.84).
Conclusion
We identify substantial variability in the time to first on-treatment LDL measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL monitoring and statin adherence. We show its subsequent impact on long term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimise treatment efficacy, safety, and long-term clinical outcomes.
